Results of Phase 2B Clinical Trial Testing New Drug-Resistant TB Treatment Published in Lancet Respiratory Medicine

November 13, 2019

November 13, 2019 – Results of the Phase 2B trial, known as NC-005 have been published in The Lancet Respiratory Medicine. The NC-005 trial was designed to test the potential of the BPaMZ and BPaZ regimens to shorten therapy in patients with drug-sensitive tuberculosis (TB) and multidrug-resistant TB. NC-005 enrolled 240 patients across 10 sites in Uganda, Tanzania and South Africa. BPaMZ is a four-drug regimen comprised of four presently approved drugs: bedaquiline (B), pretomanid (Pa), moxifloxacin (M), and pyrazinamide (Z). BPaZ is a three-drug regimen consisting of bedaquiline (B), pretomanid (Pa), and pyrazinamide (Z).

Based on data from NC-005, the BPaMZ regimen is now being tested in the pivotal SimpliciTB trial. SimpliciTB launched in 2018 and spans four continents. Enrollment is expected to be complete by early 2020.